Skip to main content
RHYTHM BIOSCIENCES LIMITED logo

RHYTHM BIOSCIENCES LIMITED — Investor Relations & Filings

Ticker · RHY ISIN · AU000000RHY2 LEI · 549300QOAISQ3ESJLP59 ASX Professional, scientific and technical activities
Open in API
Filings indexed 629 across all filing types
Latest filing 2026-05-25 Regulatory Filings
Country AU Australia
Listing ASX RHY

About RHYTHM BIOSCIENCES LIMITED

https://rhythmbio.com/

Rhythm Biosciences Limited specializes in the development and commercialization of blood-based diagnostic technology for early cancer detection. The company’s primary product, ColoSTAT®, is a minimally invasive blood test designed to identify colorectal cancer by measuring specific protein biomarkers associated with the disease. ColoSTAT® is engineered to provide a reliable, cost-effective, and patient-friendly alternative to traditional screening methods, such as fecal immunochemical tests (FIT). The technology targets the global mass screening market, specifically addressing the needs of individuals who are non-compliant with current stool-based testing protocols. By facilitating higher screening participation rates, the company focuses on the early identification of colorectal cancer to improve clinical outcomes and survival rates through timely medical intervention.

Recent filings

Filing Released Lang Actions
ColoSTAT Access Program Gains Momentum 4 pages 494.1KB
Regulatory Filings Classification · 15% confidence The document is an ASX announcement corporate press release providing an operational update on the ColoSTAT® Clinical Access Program, describing program enrollment, strategic outlook and CEO commentary. It does not contain financial results or presentation slides, is not an earnings release, proxy material, legal or regulatory filing, share transaction, capital structure change or other specialized category. It is a general ASX announcement and falls into the miscellaneous “Regulatory Filings” (RNS) fallback category for announcements that do not fit a more specific filing type.
2026-05-25 English
Investor Presentation 9 pages 1.0MB
Investor Presentation Classification · 92% confidence The document is a slide deck for a “Quarterly Investor Webinar” containing a welcome, disclaimer, company and commercial updates, and forward-looking statements, but does not present formal financial statements. It is clearly an investor presentation used to communicate strategy, progress, and highlights to investors rather than a regulatory filing or financial report itself. Therefore, it matches the “Investor Presentation (IP)” category.
2026-05-12 English
ColoSTAT Demonstrates Early Clinical Adoption 3 pages 489.0KB
Capital/Financing Update Classification · 90% confidence The document is an ASX announcement dated 6th May 2026 from Rhythm Biosciences. It discusses early clinical adoption and commercial rollout of the ColoSTAT® blood-based colorectal cancer test, including case studies and CEO commentary. The content focuses on commercial progress, clinical use cases, and an upcoming investor webinar. There are no financial statements, detailed financial performance data, nor regulatory filings or voting results. The document is a corporate announcement about product adoption and commercial updates rather than a formal financial report or regulatory filing. It is not an earnings release, annual report, or interim report. The document is best classified as a Capital/Financing Update (CAP) because it provides an update on commercial rollout and market adoption, which relates to the company's capital and commercial progress.
2026-05-05 English
Investor Webinar 1 page 389.8KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 5th May 2026 from Rhythm Biosciences Ltd. It announces an upcoming investor webinar where the CEO and team will provide updates on recent progress and commercial developments. The text invites shareholders to register and submit questions for the webinar. There is no financial data, no detailed report, no voting results, no regulatory filing, no audit information, no earnings release, and no other formal report content. The document is essentially an announcement of an event (investor webinar) and not a report or transcript itself. It is also relatively short (3711 characters). Therefore, it fits best as a Regulatory Filing (RNS) since it is a general regulatory announcement that does not fit other categories.
2026-05-04 English
Quarterly Activities Report and Appendix 4C 11 pages 911.8KB
Interim / Quarterly Report Classification · 95% confidence The document is an ASX announcement dated 30 April 2026, providing a detailed business update and Appendix 4C cash flow statement for the quarter ended 31 March 2026 (Q3 FY26). It includes operational highlights, commercial milestones, partnership updates, and financial position commentary. The Appendix 4C is a standard quarterly cash flow report required by the ASX for listed companies, which is a form of interim/quarterly reporting. The document contains substantive financial data and analysis for the quarter, not just a brief announcement or reference to a report. Therefore, it fits the definition of an Interim / Quarterly Report (IR).
2026-04-29 English
RHYO Underwriting Update 1 page 705.6KB
Capital/Financing Update Classification · 90% confidence The document is an ASX announcement providing an update on the underwriting of RHYO options by CPS Capital Group, describing a shortfall in proceeds and confirming no change to issued capital. This clearly relates to financing activities and capital structure. Therefore it falls under the Capital/Financing Update category.
2026-04-27 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.